We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

138 hedge funds and large institutions have $1.9B invested in Ventyx Biosciences in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

10% more capital invested

Capital invested by funds: $1.73B → $1.9B (+$169M)

2.78% more ownership

Funds ownership: 89.91%92.69% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

9% less call options, than puts

Call options by funds: $9.34M | Put options by funds: $10.3M

8% less funds holding

Funds holding: 150138 (-12)

43% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 23

Holders
138
Holders Change
-12
Holders Change %
-8%
% of All Funds
2.19%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
13
Increased
61
Reduced
44
Closed
23
Calls
$9.34M
Puts
$10.3M
Net Calls
-$921K
Net Calls Change
+$23.5M
Name Holding Trade Value Shares
Change
Change in
Stake
VC
26
Vivo Capital
California
$14.7M
Northern Trust
27
Northern Trust
Illinois
$14.5M +$1.23M +35,581 +9%
AG
28
Artal Group
Luxembourg
$14.1M -$113K -3,280 -0.8%
N
29
Nuveen
North Carolina
$13.4M +$731K +21,158 +6%
Charles Schwab
30
Charles Schwab
California
$12.6M +$3.73M +107,997 +42%
APM
31
Avidity Partners Management
Texas
$12.3M -$11.7M -337,600 -49%
O
32
OrbiMed
New York
$11.8M -$6.94M -200,600 -37%
Marshall Wace
33
Marshall Wace
United Kingdom
$11.6M +$3.28M +94,738 +39%
Morgan Stanley
34
Morgan Stanley
New York
$9.87M -$7.96M -230,184 -45%
GC
35
GMT Capital
Georgia
$9.75M
JFG
36
Jefferies Financial Group
New York
$9.5M +$5.19M +150,000 +121%
Victory Capital Management
37
Victory Capital Management
Texas
$9.02M -$2.73M -79,066 -23%
Hudson Bay Capital Management
38
Hudson Bay Capital Management
Connecticut
$8.63M +$5.29M +153,000 +160%
American Century Companies
39
American Century Companies
Missouri
$8.61M -$80.3K -2,323 -0.9%
Barclays
40
Barclays
United Kingdom
$7.93M +$7.08M +204,762 +873%
LGM
41
Logos Global Management
California
$7.81M -$864K -25,000 -10%
Balyasny Asset Management
42
Balyasny Asset Management
Illinois
$7.54M +$7.51M +217,151 New
ACP
43
Acuta Capital Partners
California
$7.13M +$2.01M +58,059 +39%
WP
44
Woodline Partners
California
$7.08M +$1.86M +53,783 +36%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$5.7M +$534K +15,450 +10%
JP Morgan Chase
46
JP Morgan Chase
New York
$5.54M -$834K -24,111 -13%
TD Asset Management
47
TD Asset Management
Ontario, Canada
$5.4M +$1.66M +48,121 +45%
NCM
48
Nantahala Capital Management
Connecticut
$5.13M -$1.56M -45,048 -23%
HighTower Advisors
49
HighTower Advisors
Illinois
$4.34M -$2.49K -72 -0.1%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$3.67M -$885K -25,605 -20%

VTYX Hedge Fund Activity: Q3 2023 in Review

138 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2023, worth a combined $1.9B — up 9.8% from $1.73B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of VTYX and 13 opened new positions — a net loss of 10 holders — while 44 trimmed existing stakes and 61 added.

The largest buyer was Adage Capital Partners, adding an estimated $30.9M. The largest seller was Lord, Abbett & Co, cutting an estimated $20.3M.

  • 138 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2023, down from 150 in Q2 2023.
  • Funds reported $1.9B of Ventyx Biosciences stock for Q3 2023, up 9.8% quarter-over-quarter.
  • 13 funds opened new Ventyx Biosciences positions in Q3 2023 and 23 closed out, a net change of -10 holders.
  • The largest Ventyx Biosciences buyer in Q3 2023 was Adage Capital Partners, an estimated $30.9M added.
  • The largest Ventyx Biosciences seller in Q3 2023 was Lord, Abbett & Co, an estimated $20.3M sold.

Based on aggregated 13F filings for Q3 2023.